# The Effects of Supplemented Conjugated Linoleic Acid on Lipid Metabolism in Cattle

**Authors:** Cheng Xiao, Elke Albrecht, Harald M. Hammon, Steffen Maak

PMC · DOI: 10.3390/ani16040550 · Animals : an Open Access Journal from MDPI · 2026-02-10

## TL;DR

This paper reviews how adding conjugated linoleic acid (CLA) to cattle diets affects their lipid metabolism, aiming to improve meat and milk quality while managing energy balance.

## Contribution

The paper provides a comprehensive review of CLA supplementation effects in cattle, focusing on t10,c12 CLA and its impact on energy balance and fat distribution.

## Key findings

- CLA supplementation can improve energy balance in dairy cows during the transition period.
- t10,c12 CLA reduces subcutaneous fat while increasing intramuscular fat in beef cattle.
- CLA's effects on lipid metabolism are inconsistent, partly due to differences in study design.

## Abstract

Milk and meat products of cattle are the main source of conjugated linoleic acid (CLA) for human nutrition. Increasing the amount of CLA in milk and meat products may be beneficial for consumers but is associated with changes in lipid metabolism of supplemented animals, which are not completely understood. Currently, CLA is supplemented into diets of high yielding dairy cows to reduce their energy deficit, when they are not able to meet the high energy demand of milk production by increased feed intake. Milk fat depression by CLA can help to avoid negative effects of energy loss and mobilization of body reserves for lactation. Furthermore, CLA was shown to reduce waste fat and to improve marbling fat in ruminants and pigs. Increasing the muscle fat content and improving meat quality without increasing other fat depots and without compromising feed efficiency are important goals in beef production. Additionally, increased CLA in meat makes it a healthier product for human nutrition. However, inconsistent results and higher costs limit the practical application of CLA supplementation. This review summarizes the current knowledge about the effects of supplemented CLA in dairy cows and beef cattle, as well as on individual cells in cell culture models.

Conjugated linoleic acid (CLA) is produced by bacterial biohydrogenation in the rumen of cattle, fulfills various biological functions, and is known for anti-obesity, anti-inflammation, anti-cancer, and other beneficial effects. It has numerous isomers, of which cis-9,trans-11 CLA accounts for 80% of total CLA, followed by trans-10,cis-12 CLA (t10,c12 CLA), with distinct molecular structures, oxidation efficiencies, activities, and functions. Different effects were observed, when isomers were individually supplemented in livestock nutrition. Currently, CLA is supplemented into the diets of dairy cows to improve the energy balance, and avoid negative effects of energy loss during the transition period. Furthermore, t10,c12 CLA was shown to reduce subcutaneous fat and to improve intramuscular fat (IMF) content in the carcasses of ruminants and pigs. Increasing the IMF content without increasing other fat depots and without compromising feed efficiency is an important goal in beef production. However, inconsistent and conflicting results were reported partly based on different study designs. This review aims to summarize studies on CLA supplementation in cattle, focusing on t10,c12 CLA and the effects of the dose, time, and method of supplementation on energy balance, milk yield and body composition, as well as on individual cells in vitro. This may improve our understanding of energy-saving and repartitioning effects of CLA in cattle.

## Linked entities

- **Chemicals:** cis-9,trans-11 CLA (PubChem CID 5280644)

## Full-text entities

- **Genes:** ACLY (ATP citrate lyase) [NCBI Gene 511135], SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 282359] {aka GLUT4}, NRF1 (nuclear respiratory factor 1) [NCBI Gene 509232], MYOG (myogenin) [NCBI Gene 281343], ACACA (acetyl-CoA carboxylase alpha) [NCBI Gene 281590] {aka ACC1, ACCA}, APOA1 (apolipoprotein A1) [NCBI Gene 281631], GCG (glucagon) [NCBI Gene 280802] {aka GLP-1, GLP-2}, KITLG (KIT ligand) [NCBI Gene 281885] {aka MGF}, PLIN1 (perilipin 1) [NCBI Gene 520598] {aka PLIN}, IGFBP2 (insulin like growth factor binding protein 2) [NCBI Gene 282260], APOA4 (apolipoprotein A4) [NCBI Gene 537301], INS (insulin) [NCBI Gene 280829], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 338446] {aka PPARGC-1A}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 281677], LIPE (lipase E, hormone sensitive type) [NCBI Gene 286879] {aka REH, hsl}, IGFBP3 (insulin like growth factor binding protein 3) [NCBI Gene 282261] {aka IGFBP-3}, THRSP (thyroid hormone responsive) [NCBI Gene 515940], LPL (lipoprotein lipase) [NCBI Gene 280843], FABP4 (fatty acid binding protein 4, adipocyte) [NCBI Gene 281759], PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 281993], PNPLA2 (patatin like phospholipase domain containing 2) [NCBI Gene 508493] {aka ATGL}, IGFI (Insulin-like growth factor 1 level) [NCBI Gene 104978413], SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 539361] {aka ADD1, SREBP-1, SREBP1}, MYOD1 (myogenic differentiation 1) [NCBI Gene 281938] {aka MyoD}, APOC3 (apolipoprotein C3) [NCBI Gene 408009], TFAM (transcription factor A, mitochondrial) [NCBI Gene 510059], FASN (fatty acid synthase) [NCBI Gene 281152], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 100139219], SCD (stearoyl-CoA desaturase) [NCBI Gene 280924] {aka SCD1}, MYH1 (myosin heavy chain 1) [NCBI Gene 281337]
- **Diseases:** insulin resistance (MESH:D007333), weight loss (MESH:D015431), MFD (MESH:D016269), cancer (MESH:D009369), carcinogenic (MESH:D011230), MECs (MESH:D009375), injury to (MESH:D014947), inflammation (MESH:D007249), fat (MESH:D004620), low-fat milk syndrome (MESH:D009800), obesity (MESH:D009765), depression (MESH:D003866), fatty liver (MESH:D005234)
- **Chemicals:** carbon (MESH:D002244), MUFA (MESH:D005229), Fatty acids (MESH:D005227), Triglycerides (MESH:D014280), Essential fatty acids (MESH:D005228), cortisol (MESH:D006854), AA (MESH:D000596), trans-10,cis-12 CLA (MESH:C496197), TC (MESH:D013667), PUFA (MESH:D005231), TG (MESH:D013866), LA (MESH:D019787), Ca2+ (-), BHBA (MESH:D020155), fat (MESH:D005223), short-chain fatty acids (MESH:D005232), plant oils (MESH:D010938), 3-methylhistidine (MESH:C028118), FA (MESH:D005492), glucose (MESH:D005947), creatinine (MESH:D003404), ketone bodies (MESH:D007657), Vaccenic acid (MESH:C050413), cholesterol (MESH:D002784), CLA (MESH:D044243), acetate (MESH:D000085), oleic acid (MESH:D019301), NEFA (MESH:D005230), palmitic acid (MESH:D019308), C18:0 (MESH:C031183), Lipid (MESH:D008055), glycogen (MESH:D006003), citrate (MESH:D019343), ALA (MESH:D017962), cis-9,trans-11 CLA (MESH:C503589), phospholipid (MESH:D010743)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Sus scrofa (pig, species) [taxon 9823], PX clade (clade) [taxon 569578], Bos taurus (bovine, species) [taxon 9913]
- **Cell lines:** 3T3-L1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0123), L6 myoblasts — Homo sapiens (Human), Transformed cell line (CVCL_VG47), L6 — Mus musculus (Mouse), Hybridoma (CVCL_XK50), C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937381/full.md

## References

151 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937381/full.md

---
Source: https://tomesphere.com/paper/PMC12937381